Department of Medicine, University College London Medical School, London, UK.
Nephrol Dial Transplant. 2012 Jan;27(1):34-41. doi: 10.1093/ndt/gfr736.
Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients.
肝肾综合征（HRS）定义为终末期肝硬化患者出现肾功能障碍，而无其他可识别的肾衰竭原因。HRS 的预后仍然很差，没有肝移植的中位生存期<6 个月。然而，对 HRS 发病机制的理解导致了使用血管加压素和白蛋白来增加肾灌注和平均动脉血压的治疗方法的引入，这导致约 50%的患者肾功能得到改善。
